Isolated Chicago communities secure money for a coveted transit project before Trump takes office
Caitlin Clark effect hasn't reversed the decades-long decline in girls basketball participation
The water was their livelihood. Now Thailand's sea nomads work to preserve a vanishing way of life
China says US is 'playing with fire' after latest military aid for Taiwan
Winter is hitting Gaza and many Palestinians have little protection from the cold
China calls Taiwan a 'red line', criticises new US military aid to island
Trump says he might demand Panama hand over canal
China's Nio says new Firefly EV to go on sale in Europe in H1 2025
Howard throws 2 TD passes to Smith to help Ohio State rout Tennessee 42-17 in CFP
JuJu Watkins and No. 7 USC hold off Paige Bueckers and fourth-ranked UConn 72-70
(Reuters) -The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.
Any recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use has to be formally approved by the European Commission, which usually follows the regulator's decision.
The vaccine, branded Arexvy, was approved by the U.S. Food and Drug Administration in June but the Centers for Disease Control and Prevention (CDC) did not recommend RSV shots for adults under 60 years.
The CDC had recommended that adults aged 75 and older, as well as those between the ages of 60 and 74 at an increased risk of severe RSV due to medical conditions, should receive shots against the virus.
The recommendation downsized GSK's U.S. market for the shot in 2024-25 from 93 million to about 55 million, according to analysts.
GSK had forecast peak annual sales of more than 3 billion pounds for the vaccine.
(Reporting by Prerna Bedi in Bengaluru; Editing by Shounak Dasgupta)
